Press Releases
-
12202503Press ReleasesGWOXI Stem Cell Secures Invention Patent for Diabetes Cell TherapyGwo Xi Stem Cell’s diabetes therapy candidate “GXIPC1®” has successfully secured patents in the United States, China, and Taiwan.
-
17202502Press ReleasesGWOXI PIC/S GMP Cell Preparation Factory Is Expected to Obtain Certification by October 2025In preparation for future drug approval and global expansion, Gwo Xi Stem Cell is striving to apply PIC/S GMP certification by the end of October in 2025.
-
12202501Press ReleasesTapping the Booming Pet Economy, GWOXI Stem Cell Expands into Veterinary Regenerative Medicine
Gwo Xi Stem Cell has established partnerships with multiple veterinary clinics, veterinary associations, and distribution partners to build a comprehensive veterinary regenerative medicine network, while continuously expanding its presence in the market.
-
16202412Press ReleasesTaiwan–Vietnam Cross-Border Collaboration Completes Phase I Clinical Trial of Stem Cell Therapy for Diabetes. Preliminary Result
Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) announced on December 9 that it has obtained the results of its Phase I human clinical trial for type I diabetes in collaboration with Vietnam.
-
25202411Press ReleasesGWOXI Stem Cell Capitalizes on Super-Aged Society and Taiwan’s Regenerative Medicine Act; Stem Cell Therapy Product for ChronicLooking ahead, Dr. Ming-His Chuang explained that Gwo Xi Stem Cell’s primary strategy is to prioritize domestic drug approval, while pursuing out-licensing and strategic partnerships internationally.